Read by QxMD icon Read

Gastric Cancer

Irene Gullo, Patrícia Oliveira, Maria Athelogou, Gilza Gonçalves, Marta L Pinto, Joana Carvalho, Ana Valente, Hugo Pinheiro, Sara Andrade, Gabriela M Almeida, Ralf Huss, Kakoli Das, Patrick Tan, José C Machado, Carla Oliveira, Fátima Carneiro
BACKGROUND: Gastric cancer with lymphoid stroma (GCLS) is characterized by prominent stromal infiltration of T-lymphocytes. The aim of this study was to investigate GCLS biology through analysis of clinicopathological features, EBV infection, microsatellite instability (MSI), immune gene-expression profiling and PD-L1 status in neoplastic cells and tumor immune microenvironment. METHODS: Twenty-four GCLSs were analyzed by RNA in situ hybridization for EBV (EBER), PCR/fragment analysis for MSI, immunohistochemistry (PD-L1, cytokeratin, CD3, CD8), co-immunofluorescence (CK/PD-L1, CD68/PD-L1), NanoString gene-expression assay for immune-related genes and PD-L1 copy number alterations...
May 19, 2018: Gastric Cancer
Hyun Jin Oh, Chul-Hyun Lim, Seung Bae Yoon, Han Hee Lee, Jin Su Kim, Yu Kyung Cho, Jae Myung Park, Myung-Gyu Choi
BACKGROUND: Self-expandable metallic stents in the upper gastrointestinal tract are used for treating malignant esophageal or gastroduodenal outlet obstructions and fistulas. Recently, self-expandable metallic stent use has been expanded to benign esophageal or gastroduodenal strictures and post-operative complications. However, there is scarce data available regarding efficacy, long-term complications, and outcomes with the use of self-expandable metallic stent in benign disease, especially post-gastrectomy complications...
May 14, 2018: Gastric Cancer
Jing Zhang, Zhonglin Zhu, Huijing Wu, Zhilong Yu, Zeyin Rong, Zai Luo, Yiwei Xu, Kejian Huang, Zhengjun Qiu, Chen Huang
BACKGROUND: Podocalyxin-like 1 (PODXL) was reported to be closely associated with the development of various cancers, yet its functional roles and molecular mechanisms remain vague. The aim of our study was to investigate the clinical significance, biological function and molecular mechanism of PODXL in gastric cancer (GC). METHODS: The level of PODXL in GC tissues was detected applying GC tissues microarray, fresh GC tissues and public database (Oncomine). The invasion, metastasis and tumorigenesis role of PODXL were performed in vitro and in vivo...
May 10, 2018: Gastric Cancer
Ziyu Li, Yinkui Wang, Fei Shan, Xiangji Ying, Zhouqiao Wu, Kan Xue, Rulin Miao, Yan Zhang, Jiafu Ji
BACKGROUND: This study aims to evaluate the new ypTNM staging system in Chinese gastric cancer patients. METHODS: We conducted retrospective survival and regression analyses using a database of gastric cancer patients who underwent neoadjuvant chemotherapy at the Peking University Cancer Hospital and Institute from January 2007 to January 2015. RESULTS: A total of 473 patients were included in the study with 28 pathological complete response (pCR) cases, 3 ypT0N1 cases, 65 stage I cases, 126 stage II cases, and 251 stage III cases...
May 10, 2018: Gastric Cancer
Yosuke Atsumi, Yasushi Rino, Hiroo Wada, Yuichi Kitani, Yukihiro Ozawa, Toru Aoyama, Takashi Oshima, Norio Yukawa, Takaki Yoshikawa, Munetaka Masuda
BACKGROUND: Several retrospective studies have shown that bone disorders occur after gastric cancer surgery. This study was designed to prospectively evaluate the changes in bone metabolism after gastrectomy for gastric cancer. METHODS: We prospectively enrolled 39 men with early gastric cancer who underwent gastrectomy. We excluded women to avoid the effects of menopause. We employed dual energy X-ray absorptiometry (DEXA) to measure bone mineral density (BMD) of the lumbar spine...
May 10, 2018: Gastric Cancer
Naruhiko Ikoma, Prajnan Das, Wayne Hofstetter, Jaffer A Ajani, Jeannelyn S Estrella, Hsiang-Chun Chen, Xuemei Wang, Rashida A Callender, Cong Zhu, Christina L Roland, Keith F Fournier, Janice N Cormier, Paul Mansfield, Brian D Badgwell
BACKGROUND: The benefit of preoperative chemoradiation (CXRT) over preoperative chemotherapy alone ("chemotherapy" hereafter) is unknown. By analyzing the National Cancer Database (NCDB), we investigated whether preoperative CXRT improves the incidence of primary tumor pathologic complete response (ypT0) and overall survival (OS) compared with preoperative chemotherapy in patients with gastric cancer. METHODS: Patients with non-metastatic gastric adenocarcinoma who underwent CXRT or chemotherapy followed by gastrectomy were included...
May 5, 2018: Gastric Cancer
Zhaolun Cai, Yiqiong Yin, Yuan Yin, Chaoyong Shen, Jian Wang, Xiaonan Yin, Zhixin Chen, Ye Zhou, Bo Zhang
BACKGROUND: Different adjuvant treatments are available for patients with gastric cancer, but conventional meta-analyses performing direct comparisons between two alternative treatments did not have enough power to compare all the adjuvant treatments. Thus, we did a network meta-analysis summarizing the direct and indirect comparisons to identify the optimum treatment. METHODS: We systematically searched for RCTs of adjuvant treatments for gastric cancer comparing two or more of the following treatments: surgery alone, radiotherapy with fluoropyrimidine, S-1-based regimens, and XELOX...
May 4, 2018: Gastric Cancer
Jung Hwan Yoon, In-Hye Ham, Olga Kim, Hassan Ashktorab, Duane T Smoot, Suk Woo Nam, Jung Young Lee, Hoon Hur, Won Sang Park
BACKGROUND: Gastrokine 1 (GKN1) plays important roles in maintaining mucosal homeostasis, and in regulating cell proliferation and differentiation. Here, we determined whether GKN1 is a potential theragnostic marker for gastric cancer. METHODS: We identified GKN1 binding proteins using the protein microarray assay and investigated whether GKN1 is one of the exosomal cargo proteins by western blot, immunoprecipitation, and immunofluorescent assays. Cell proliferation and apoptosis were analyzed by MTT, BrdU incorporation, flow cytometry, and western blot assays...
April 27, 2018: Gastric Cancer
Yosuke Kano, Manabu Ohashi, Naoki Hiki, Daisuke Takahari, Keisho Chin, Kensei Yamaguchi, Yasuo Tsuda, Yoshiaki Shoji, Itaru Yasufuku, Kojiro Eto, Satoshi Ida, Koshi Kumagai, Souya Nunobe, Takeshi Sano
BACKGROUND: One-year adjuvant S-1 monotherapy following D2 gastrectomy has been the Japanese treatment standard for pathological stage II or III gastric cancer since the Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer (ACTS-GC) was concluded in 2007. Trial patients were selected according to the 13th edition of the Japanese classification (JC-13). The JC-13 and the TNM classification underwent major revisions in 2010 (JC-14/TNM-7). However, neither the recent therapeutic results for patients with stage II/III disease defined by the current system nor comparisons with the ACTS-GC-results have been reported...
April 26, 2018: Gastric Cancer
Takashi Akutagawa, Shigehisa Aoki, Mihoko Yamamoto-Rikitake, Ryuichi Iwakiri, Kazuma Fujimoto, Shuji Toda
BACKGROUND: Early local tumor invasion in gastric cancer results in likely encounters between cancer cells and submucosal and subserosal adipose tissue, but these interactions remain to be clarified. Microenvironmental mechanical forces, such as fluid flow, are known to modulate normal cell kinetics, but the effects of fluid flow on gastric cancer cells are poorly understood. We analyzed the cell kinetics and chemosensitivity in gastric cancer using a simple in vitro model that simultaneously replicated the cancer-adipocyte interaction and physical microenvironment...
April 25, 2018: Gastric Cancer
Atsuko Ohki, Nobutsugu Abe, Eri Yoshimoto, Yoshikazu Hashimoto, Hirohisa Takeuchi, Gen Nagao, Tadahiko Masaki, Toshiyuki Mori, Yasuo Ohkura, Masanori Sugiyama
PURPOSE: Intragastric free cancer cells in patients with gastric cancer have rarely been studied. The purpose of this study was to investigate the detection rate of intragastric free cancer cells in gastric washes using two types of solutions during endoscopic examination. We further clarified risk factors affecting the presence of exfoliated free cancer cells. METHODS: A total of 175 patients with gastric cancer were enrolled. Lactated Ringer's solution (N = 89) or distilled water (DW; N = 86) via endoscopic working channel was sprayed onto the tumor surface, and the resultant fluid was collected for cytological examination...
April 25, 2018: Gastric Cancer
Brian De, Ryan Rhome, Vikram Jairam, Umut Özbek, Randall F Holcombe, Michael Buckstein, Celina Ang
BACKGROUND: Evidence regarding gastric cancer patients < 40 years old is limited. This study examines young adults with gastric adenocarcinoma in the National Cancer Database to describe demographics and treatment practices, and to develop a nomogram to predict survival. METHODS: The database was queried for adult patients diagnosed with gastric adenocarcinoma from 2004 to 2013. Patients were stratified into two age groups: <40 and ≥ 40 years. The database was analyzed to compare demographics, clinical characteristics, and treatments used for each group...
April 24, 2018: Gastric Cancer
Chihiro Kondoh, Shigenori Kadowaki, Azusa Komori, Yukiya Narita, Hiroya Taniguchi, Takashi Ura, Masashi Ando, Kei Muro
BACKGROUND: Although nivolumab showed survival benefit in patients with advanced gastric cancer (AGC) progressing after standard chemotherapy, there is a lack of data regarding oxaliplatin-based chemotherapy in this clinical setting. METHODS: We retrospectively evaluated the efficacy and safety of oxaliplatin with l-leucovorin and bolus/continuous infusion of 5-fluorouracil as salvage treatment in patients with AGC refractory or intolerant to fluoropyrimidines, cisplatin, taxanes, and irinotecan...
April 16, 2018: Gastric Cancer
Jung Hwan Lee, Boram Park, Jungnam Joo, Myeong-Cherl Kook, Young-Il Kim, Jong Yeul Lee, Chan Gyoo Kim, Il Ju Choi, Bang Wool Eom, Hong Man Yoon, Keun Won Ryu, Young-Woo Kim, Soo-Jeong Cho
BACKGROUND: The effects of obesity on prognosis in gastric cancer are controversial. AIMS: To evaluate the association between body mass index (BMI) and mortality in patients with gastric cancer. METHODS: A single-institution cohort of 7765 patients with gastric cancer undergoing curative gastrectomy between October 2000 and June 2016 was categorized into six groups based on BMI: underweight (< 18.5 kg/m2 ), normal (18.5 to < 23 kg/m2 ), overweight (23 to < 25 kg/m2 ), mildly obese (25 to < 28 kg/m2 ), moderately obese (28 to < 30 kg/m2 ), and severely obese (≥ 30 kg/m2 )...
April 12, 2018: Gastric Cancer
Charles J Cho, Hyo Jeong Kang, Yeon-Mi Ryu, Young Soo Park, Hui Jeong Jeong, Young-Mi Park, Hyun Lim, Jeong Hoon Lee, Ho June Song, Hwoon-Yong Jung, Sang-Yeob Kim, Seung-Jae Myung
BACKGROUND: Gastric cancer with lymphoid stroma (GCLS) is pathologically characterized by poorly developed tubular structures with a prominent lymphocytic infiltration. Its clinical and prognostic features differ in patients positive and negative for Epstein-Barr virus (EBV) infection. This study analyzed the expression of programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1), and the density of tumor-infiltrating lymphocytes (TILs) including CD3+ and CD8+ T cells, as well as their prognostic significance in patients with GCLS...
April 7, 2018: Gastric Cancer
Takahito Sugase, Tsuyoshi Takahashi, Satoshi Serada, Minoru Fujimoto, Tomoharu Ohkawara, Kosuke Hiramatsu, Toshirou Nishida, Seiichi Hirota, Yurina Saito, Koji Tanaka, Yasuhiro Miyazaki, Tomoki Makino, Yukinori Kurokawa, Makoto Yamasaki, Kiyokazu Nakajima, Kazuhiro Hanasaki, Tadamitsu Kishimoto, Masaki Mori, Yuichiro Doki, Tetsuji Naka
BACKGROUND: Most of the gastrointestinal stromal tumors (GIST) have mutations in the KIT gene, encoding a receptor tyrosine kinase. Imatinib, a receptor tyrosine kinase inhibitor, is the first-line therapy for unresectable and metastatic GISTs. Despite the revolutionary effects of imatinib, some patients are primarily resistant to imatinib and many become resistant because of acquisition of secondary mutations in KIT. This study investigated the antitumor effects of SOCS1 gene therapy, which targets several signaling pathways...
April 5, 2018: Gastric Cancer
Kuka Ishioka, Hiroyuki Masaoka, Hidemi Ito, Isao Oze, Seiji Ito, Masahiro Tajika, Yasuhiro Shimizu, Yasumasa Niwa, Shigeo Nakamura, Keitaro Matsuo
BACKGROUND: Aldehyde dehydrogenase 2 (ALDH2; rs671, Glu504Lys) and alcohol dehydrogenase 1B (ADH1B; rs1229984, His47Arg) polymorphisms have a strong impact on carcinogenic acetaldehyde accumulation after alcohol drinking. To date, however, evidence for a significant ALDH2-alcohol drinking interaction and a mediation effect of ALDH2/ADH1B through alcohol drinking on gastric cancer have remained unclear. We conducted two case-control studies to validate the interaction and to estimate the mediation effect on gastric cancer...
April 3, 2018: Gastric Cancer
Lisette Nieuwenhuis, Piet A van den Brandt
BACKGROUND: Nut consumption has been associated with reduced cancer-related mortality. However, it is unclear whether nut consumption also reduces the risk of esophageal and gastric cancer subtypes. We prospectively investigated the relationship of tree nut, peanut, and peanut butter intake with risk of esophageal squamous cell carcinoma (ESCC), esophageal adenocarcinoma (EAC), gastric cardia adenocarcinoma (GCA), and gastric non-cardia adenocarcinoma (GNCA) in the Netherlands Cohort Study...
March 28, 2018: Gastric Cancer
Yusuke Horiuchi, Junko Fujisaki, Noriko Yamamoto, Shoichi Yoshimizu, Akiyoshi Ishiyama, Toshiyuki Yoshio, Toshiaki Hirasawa, Yorimasa Yamamoto, Masatsugu Nagahama, Hiroshi Takahashi, Tomohiro Tsuchida
BACKGROUND: It is unknown how the accuracy rate of diagnostic demarcation of undifferentiated-type early gastric cancers (UD-type EGCs) differs between patients uninfected with Helicobacter pylori (H. pylori) and patients with and without H. pylori eradication. This study assessed and compared the diagnostic accuracy rate in the H. pylori-uninfected group and the non-H. pylori eradication and H. pylori eradication groups. METHODS: Subjects were 81 patients with 81 lesions who underwent endoscopic submucosal dissection between January 2010 and January 2015...
March 13, 2018: Gastric Cancer
Naoto Takahashi, Mitsuro Kanda, Takaki Yoshikawa, Nobuhiro Takiguchi, Kazumasa Fujitani, Katsufumi Miyamoto, Yuichi Ito, Osamu Takayama, Motohiro Imano, Norio Mitsumori, Junichi Sakamoto, Satoshi Morita, Yasuhiro Kodera
BACKGROUND: Intraperitoneal administration of paclitaxel had been considered a promising option to treat peritoneal metastasis, the most frequent pattern of recurrence in gastric cancer after D2 gastrectomy, but its safety and efficacy after gastrectomy had not been fully explored. METHODS: A phase II randomized comparison of postoperative intraperitoneal (IP) vs. intravenous (IV) paclitaxel was conducted. Patients with resectable gastric linitis plastica, cancer with minimal amount of peritoneal deposits (P1), or cancer positive for the peritoneal washing cytology (CY1) were eligible...
March 13, 2018: Gastric Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"